Hjem › Follikulært lymfom › Massachusetts › Boston
Follikulært lymfom kliniske forsøg i Boston, MA
17 studier for Follikulært lymfom søger deltagere på steder i og omkring Boston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RekruttererFase 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RekruttererFase 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
RekruttererFase 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RekruttererFase 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekruttererFase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RekruttererFase 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RekruttererFase 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
RekruttererFase 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RekruttererFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Follikulært lymfom forsøg i andre byer
- New York City, NY24 studier
- Milwaukee, WI19 studier
- Nashville, TN18 studier
- Houston, TX18 studier
- Baldwin Park, CA16 studier
- Seattle, WA15 studier
- Durham, NC15 studier
- Columbus, OH13 studier
- Salt Lake City, UT13 studier
- San Antonio, TX12 studier
- Chicago, IL12 studier
- Philadelphia, PA12 studier
Andre studier i Boston
- Brystkræft111 studier
- Ikke-småcellet lungecancer90 studier
- Kræft (alle typer)86 studier
- Colorektal kræft63 studier
- Metastatisk cancer63 studier
- Lungecancer62 studier
- Ægstockræft61 studier
- Prostatakræft59 studier
- Depression52 studier
- Livmoderslimhindekræft50 studier
- Hjertesvigt44 studier
- Akut myeloid leukæmi44 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.